The global life sciences landscape has become markedly more competitive over the past decade, with investment decisions increasingly driven by a clear set of commercial fundamentals: market scale, speed to revenue and increasingly complex geopolitical factors. While much of the public debate has focused on whether the UK is ‘falling behind’, the reality is more nuanced.
Pharmaceutical companies are not making decisions based on sentiment – they are allocating capital based on where they can achieve the strongest and most sustainable return. In that context, the UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates.
This shift towards more disciplined capital allocation is already evident in our C-suite barometer data, where life sciences leaders report an investment index of just 53% – well below the UK cross-sector average – highlighting a more cautious and selective approach to where and how capital is deployed. In practice, this is leading companies to evaluate investment locations more closely, with much of the recent movement towards the US focused on new facilities and expansion activity rather than wholesale relocation from existing European sites.
Why Europe is being squeezed
Europe’s position in the global life sciences market is being steadily compressed between two increasingly dominant models. In the US, high pricing flexibility and rapid patient access continue to make it the most commercially attractive launch market. At the same time, China is rapidly scaling its innovation ecosystem, supported by state-backed investment, faster clinical trial timelines and a growing domestic market. Against this backdrop, Europe increasingly risks appearing comparatively fragmented and commercially constrained, particularly as lower drug pricing environments continue to affect investment attractiveness.
Read the article in full here.